The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Reducing preventable ED visits in patients with advanced NSCLC: Collective insights from three cancer centers.
 
Wendi Waugh
No Relationships to Disclose
 
Devika Govind Das
No Relationships to Disclose
 
Nancy N Thomas
Stock and Other Ownership Interests - CVS
 
Elana Plotkin
No Relationships to Disclose
 
Ravi Salgia
Consulting or Advisory Role - Abbvie; AstraZeneca; Iovance Biotherapeutics; Novartis
Speakers' Bureau - AstraZeneca; Merck
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Mark A. Socinski
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Lilly; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca/MedImmune; Genentech; Janssen; Lilly; Novartis
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; G1 Therapeutics; Genentech; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Sanofi/Regeneron
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Spectrum Pharmaceuticals (Inst)
 
Percy Lee
Employment - MD Anderson Cancer Center
Leadership - The Radiosurgery Society
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Varian Medical Systems; ViewRay
Consulting or Advisory Role - Genentech/Roche; Varian Medical Systems; ViewRay
Speakers' Bureau - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Varian Medical Systems; ViewRay; ViewRay
 
Matthew Smeltzer
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Joseph Kim
No Relationships to Disclose
 
Leigh Boehmer
Consulting or Advisory Role - AstraZeneca; Pfizer